Using an unlevered Free Cash Flow to Firm (FCFF) model, we project Maze Therapeutics, Inc.'s cash flows over 5 years with line-by-line expense modeling. Revenue is projected revenue growing from 5.0% to 83.3% annually, with expenses (COGS, SG&A, R&D) held at historical ratios. Depreciation is computed from a vintage matrix based on a 5-year useful life. Working capital is modeled using historical turnover days (DSO 45, DPO 30, DIO 60). At a 8.7% WACC with mid-year discounting, the terminal value (0% of enterprise value) is derived by applying the industry peer median EV/EBITDA multiple of 3.5x to Year 6 EBITDA. After subtracting net debt, the equity value implies a fair price of $2.10 per share, suggesting MAZE is overvalued by 91.9% at the current price of $26.03.
Adjust parameters to explore scenarios. Changes are for exploration only and do not affect saved valuations.
| 2025 | 2026 | 2027 | 2028 | 2029 | Terminal | |
|---|---|---|---|---|---|---|
| Profit Before Tax | -31 | -1 | -1 | -7 | -12 | -13 |
| (−) Net Interest | 4 | 0 | 0 | 1 | 1 | 1 |
| (+) D&A | 0 | 0 | 0 | 0 | 1 | 1 |
| EBITDA | -27 | -1 | -0 | -6 | -11 | -11 |
| (−) Tax | 0 | 0 | 0 | 0 | 0 | — |
| (−) CapEx | 1 | 0 | 0 | 0 | 0 | — |
| (−) ΔWC | 31 | -28 | -0 | 5 | 5 | — |
| Free Cash Flow (FCF) | -59 | 27 | -0 | -11 | -16 | — |
| Peers' EBITDA Multiple | 3.5x | |||||
| Terminal Value | -38 | |||||
| WACC / Discount Rate | 8.71% | |||||
| Timing of FCF (mid year) | 0.5 | 1.5 | 2.5 | 3.5 | 4.5 | 5 |
| Present Value of FCF | -57 | 24 | -0 | -8 | -11 | -25 |
| Enterprise Value | -78 | |||||
| Projection Period | -53 | 0.0% | ||||
| Terminal Value | -25 | 0.0% | ||||
| (−) Current Net Debt | (170) | |||||
| Equity Value | 92 | |||||
| (÷) Outstanding Shares | 44M | |||||
| Fair Price | $2 | -91.9% | ||||
| WACC \ EV/EBITDA Exit Multiple | 1.0x | 1.5x | 3.5x | 5.5x | 7.5x |
|---|---|---|---|---|---|
| 6.7% | $2 | $2 | $2 | $2 | $1 |
| 7.7% | $2 | $2 | $2 | $2 | $1 |
| 8.7% | $3 | $2 | $2 | $2 | $1 |
| 9.7% | $3 | $2 | $2 | $2 | $2 |
| 10.7% | $3 | $2 | $2 | $2 | $2 |
Current price: $26.03. Green = undervalued, Red = overvalued.
Based on default parameters
Using the industry peer median P/E Multiples multiple (trailing + forward), Maze Therapeutics, Inc. (MAZE) has a fair value of $9.33 based on 1 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE | 1,140 | 334.6x | — |
| BioCryst Pharmaceuticals, Inc. | 1,988 | 7.8x | 34.5x |
| Industry Median | 7.8x | 34.5x | |
| (*) Profit after tax | 52 | ||
| Equity Value | 409 | ||
| (/) Outstanding shares | 44 | ||
| Fair Price | $9 | ||
Using the industry peer median EV/EBITDA multiple (trailing + forward), Maze Therapeutics, Inc. (MAZE) has a fair value of $6.59 based on 2 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE | 1,140 | 15.9x | 213.5x |
| BioCryst Pharmaceuticals, Inc. | 1,988 | 6.8x | 9.2x |
| Zymeworks Inc. | 1,920 | 0.2x | 0.1x |
| Industry Median | 3.5x | 4.6x | |
| (*) EBITDA | 61 | 5 | |
| = Enterprise Value | 216 | 21 | |
| (-) Net Debt | -170 | -170 | |
| Equity Value | 386 | 191 | |
| (/) Outstanding shares | 44 | 44 | |
| Fair Price | $9 | $4 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Maze Therapeutics, Inc. (MAZE) has a fair value of $38.72 based on 6 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Maze Therapeutics, Inc.MAZE | 1,140 | 5.8x | 77.6x |
| BioCryst Pharmaceuticals, Inc. | 1,988 | 2.7x | 3.7x |
| Zymeworks Inc. | 1,920 | 17.9x | 6.4x |
| Immunome, Inc. | 1,887 | 178.3x | — |
| Intellia Therapeutics, Inc. | 1,571 | 22.3x | 25.7x |
| Ardelyx, Inc. | 1,464 | 3.9x | 2.9x |
| Wave Life Sciences Ltd. | 1,335 | 17.6x | 21.9x |
| Industry Median | 17.7x | 6.4x | |
| (*) Revenue | 168 | 13 | |
| = Enterprise Value | 2,970 | 80 | |
| (-) Net Debt | -170 | -170 | |
| Equity Value | 3,140 | 251 | |
| (/) Outstanding shares | 44 | 44 | |
| Fair Price | $72 | $6 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.